Observational studyUnited European gastroenterology journal2024

Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.

Mariangela Allocca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.